USANA Health Sciences (NYSE:USNA) Releases FY 2026 Earnings Guidance

USANA Health Sciences (NYSE:USNA) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.950-2.290 for the period, compared to the consensus estimate of 1.950. The company issued revenue guidance of $925.0M-$1.0 billion, compared to the consensus revenue estimate of $938.7 million.

USANA Health Sciences Stock Up 3.4%

USANA Health Sciences stock traded up $0.63 during mid-day trading on Tuesday, hitting $19.19. 97,334 shares of the company’s stock were exchanged, compared to its average volume of 124,922. The company’s 50 day simple moving average is $18.58 and its 200-day simple moving average is $19.73. The firm has a market capitalization of $354.13 million, a P/E ratio of 34.89, a PEG ratio of 0.83 and a beta of 0.77. USANA Health Sciences has a fifty-two week low of $16.60 and a fifty-two week high of $38.32.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.17. USANA Health Sciences had a return on equity of 6.75% and a net margin of 1.16%.The firm had revenue of $250.22 million during the quarter, compared to analysts’ expectations of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Research analysts expect that USANA Health Sciences will post 1.95 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on USNA shares. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research note on Friday, March 27th. Zacks Research lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. Finally, Wall Street Zen cut shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce”.

Insider Buying and Selling at USANA Health Sciences

In related news, insider Joshua Foukas sold 4,461 shares of the stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $21.34, for a total transaction of $95,197.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.82% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. National Bank of Canada FI increased its position in shares of USANA Health Sciences by 166.6% in the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after acquiring an additional 1,201 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in USANA Health Sciences by 382.5% during the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after purchasing an additional 1,901 shares during the last quarter. Parallel Advisors LLC grew its stake in USANA Health Sciences by 1,354.3% in the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock valued at $76,000 after purchasing an additional 3,589 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in USANA Health Sciences by 52.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after purchasing an additional 1,327 shares in the last quarter. Finally, iSAM Funds UK Ltd acquired a new position in shares of USANA Health Sciences during the 3rd quarter worth approximately $120,000. Institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.